We reported that p62 (sequestosome 1) serves as a signaling hub in bone marrow stromal cells (BMSCs) for the formation of signaling complexes, including NFκB, p38MAPK and JNK, that are involved in the increased osteoclastogenesis and multiple myeloma (MM) cell growth induced by BMSCs that are key contributors to multiple myeloma bone disease (MMBD), and demonstrated that the ZZ domain of p62 (p62-ZZ) is required for BMSC enhancement of MMBD. We recently identified a novel p62-ZZ inhibitor, XRK3F2, which inhibits MM cell growth and BMSC growth enhancement of human MM cells. In the current study, we evaluate the relative specificity of XRK3F2 for p62-ZZ, characterize XRK3F2's capacity to inhibit growth of primary MM cells and human MM cell lines, and test the in vivo effects of XRK3F2 in the immunocompetent 5TGM1 MM model. We found that XRK3F2 induces dramatic cortical bone formation that is restricted to MM containing bones and blocked the effects and upregulation of tumor necrosis factor alpha (TNFα), an osteoblast (OB) differentiation inhibitor that is increased in the MM bone marrow microenvironment and utilizes signaling complexes formed on p62-ZZ, in BMSC. Interestingly, XRK3F2 had no effect on non-MM bearing bone. These results demonstrate that targeting p62 in MM models has profound effects on MMBD.
INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy marked by monoclonal protein production and lytic bone disease that is a major cause of patient morbidity. MM bone disease (MMBD) is marked by increased osteoclast (OCL) activity and highly suppressed or absent osteoblast (OB) activity. Adhesive interactions between MM cells and bone marrow stromal cells (BMSCs) activate multiple signaling pathways in BMSC that enhance tumor growth and bone destruction while suppressing new bone formation and contributing to chemoresistance. [1] [2] [3] [4] [5] We reported that p62 (sequestosome 1) serves as a signaling hub in BMSC for the formation of signaling complexes involved in the BMSC-induced increase in osteoclastogenesis and MM cell growth characteristic of MMBD, 6 including NFκB, p38MAPK and JNK (Figure 1a) , and recently demonstrated that the ZZ-domain of p62 (p62-ZZ) is required for BMSC enhancement of MMBD. 7 We recently identified a novel p62-ZZ inhibitor, XRK3F2 (Figure 1b) , using 3D homology modeling to predict the structure of the p62 protein and virtual screening molecular docking studies, 8 and tested XRK3F2's potential to inhibit MM cell growth and modulate the MM bone marrow microenvironment. We found that XRK3F2 inhibited murine MM cell growth, BMSC enhancement of human MM cell growth and tumor necrosis factor alpha (TNFα)-induced OCL formation by WT but not by p62 − / − OCL precursors, and that its effects were specific to p62. 9 The current study evaluates the relative specificity of XRK3F2 for p62-ZZ, XRK3F2's growth inhibition of human MM cell lines and primary human MM cells, and characterizes the in vivo efficacy of XRK3F2 in the immunocompetent 5TGM1 MM model. We report that XRK3F2 induces new bone formation in areas of high MM burden without altering non-tumor bearing bone. To evaluate potential mechanisms by which XRK3F2 induces bone formation, we tested the effects of XRK3F2 on OB differentiation and MM cell-stromal cell (pre-OB) interactions.
MATERIALS AND METHODS

Isolation of human bone marrow cells and BMSC
After obtaining informed consent, marrow aspirates were obtained from MM patients and healthy subjects. These studies were approved by the University of Pittsburgh and Indiana University IRBs. Marrow mononuclear cells were isolated and depleted of non-adherent cells as previously described 10, 11 and enriched for OCL precursors by CD11b MicroBead selection (Miltenyi Biotec Inc., Auburn, CA, USA). Adherent cells were processed as described 12 and used at passages 2-3. Human MM cells (490% purity) were isolated by magnetic cell fractionation using anti-CD138 MicroBeads (Miltenyi Biotec Inc.) and used for experiments described below. 13 
OCL formation assays
CD11b
+ cells were cultured with 10 ng/ml TNFα or 50 ng/ml RANKL (receptor activator of nuclear factor kappa-B ligand) for 48 h for western analyses, or for 21 days for osteoclastogenesis assays, as described.
10
23C6-positive multinuclear cells (containing at least three nuclei) were scored as OCL. 14 
Myeloma cell lines
MM cell lines were generously provided by Drs Steven Rosen (MM1.S), Babatunde O Oyajobi (5TGM1), Diane Jelinek (ANBL-6) Nicola Giuliani (JJN3), Suzanne Lentzsch (RPMI8226) and Louis Stancato (U266, H929). 5TGM1 cells were stably transfected with a lentiviral construct containing GFP (5TGM1-gfp) and maintained as previously described. 12 
OB differentiation assays
Primary BMSC or MC4 cells were cultured under osteogenic conditions in the presence or absence of 5TGM1 cells as described. 12 Relative expression of key OB differentiation genes was quantified using real-time PCR, as described. 12 GAPDH and 18 S were used as internal controls.
Cell proliferation assays Western blot analyses BMSC or OCL precursor cell lysates was loaded onto 7.5% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) (for V-CAM1 expression) or 10% SDS-PAGE (for cell signaling analyses) and electrophoresed under reducing conditions using precast gels (Bio-Rad Laboratories, Hercules, CA, USA), as described. 16 Antibodies used for immunoblotting included: anti-phospho PKCζ (Thr410/403), anti-phospho IκBα (Ser32), anti-phospho p38 MAPK (Thr180/Tyr182) and anti-p38 MAPK, anti-PKCζ, anti-IκBα, cleaved and uncleaved caspases 3, 7 and 9 (all from Cell Signaling, Boston, MA, USA, catalog numbers 9378, 2859, 9211, 9212, 9368 and 9242, respectively), anti-c-Fos, anti-NFATc1 and anti-V-CAM1 (Santa Cruz Biotechnology, Dallas, TX, USA, catalog numbers sc-52, sc-7294 and sc-1504, respectively), and anti-TNF-α (R&D Systems, Minneapolis, MN, USA, catalog number AF-410-NA). β-Actin was used as a control (Abcam, Cambridge, MA, USA, catalog ab49900).
Human interleukin-6 and RANKL production BMSC (2x10 5 ) was cultured in α-MEM-10% FCS for 48 h and interleukin-6 (IL-6) and RANKL production in conditioned media was quantified using commercially available ELISA kits (IL-6, R&D Systems, and RANKL, ALPCO Immunoassays, Salem, NH, USA), per the manufacturers' instructions.
Mice
Specific-pathogen-free, male C57BL/KaLwRij mice (6-12 weeks of age) were obtained from Dr Jolene Windle at Virginia Commonwealth University. Mice were maintained and handled in accordance with the Guide for the Care and Use of Laboratory Animals 17 on a protocol approved by the University of Pittsburgh IACUC. For selected experiments, primary murine BMSCs were isolated from these mice and cocultured with MM cell lines, as described. 12 BMSC from p62KO (p62 − / − ) mice and p62
littermates were isolated and maintained as previously described. 6 In vivo efficacy of XRK3F2 1x10 5 5TGM1-gfp cells in logarithmic phase growth were inoculated into one tibia (IT) of C57BL/KaLwRij mice under Nembutal anesthesia. Buprenorphine was administered as an analgesic 2 h before and for 48 h after tumor cell implantation. Supplementary Figure 1 provides a detailed schema for the in vivo studies. Briefly, animals were stratified by IgG 2b levels 2 weeks after tumor implantation and treated with either XRK3F2 (27 mg/kg/day or 40 mg/kg/day) or vehicle (0.01 ml/g in 15% hydroxyl propyl β cyclodextrin in saline/day) intraperitoneally (IP) for 5 consecutive days/week for 2 weeks. Mice were then followed for delayed effects for up to 2 weeks following treatment, or until tumors reached 2 g. Twelve animals were treated per group, based on our prior experience with tumor take in this model. 12 Doses and dosing schedules were chosen based on preliminary multidose pharmacokinetic studies (data not shown). Following euthanasia, blood was collected by cardiac puncture, bilateral tibias and femurs removed and fixed in 10% phosphate-buffered formalin for 48 h and then transferred to 70% ethanol.
IgG 2b concentrations
Plasma IgG 2b concentrations were determined using commercially available ELISA kits, according to manufacturer instructions (Bethyl Laboratories, Inc., Montgomery, TX, USA).
Radiography and micro-computed tomography
Radiographs of formalin fixed tibiae were obtained using an XPERT 80 Digital Cabinet X-ray System with energy range: 10-90 kV and tube current up to 1.0 mA (Kubtec Digital X-ray, Milford, CT, USA), and analyzed by a blinded observer. New woven bone formation was quantified using a microCT system (viva CT 40, Scanco Medical, Brüttisellen, Switzerland). Details of micro-computed tomography (μCT) analysis are in the Supplementary methods.
Histology and histomorphometry
Hind limbs were fixed as described above and decalcified in 10% EDTA for 2 weeks. Tissues were processed as previously described 18 and sections were stained with hematoxylin and eosin, and tartrate-resistant alkaline phosphatase. Tumor localization was confirmed with anti-GFP staining (Abcam). Sections were viewed on a Leica DM LB compound microscope outfitted with a Q-Imaging Micropublisher Cooled CCD color digital camera (W. Nuhsbaum Inc, McHenry, IL, USA).
Statistical analyses
For cell culture and μCT studies, results are expressed as mean ± s.d. Significance was evaluated using a two-tailed, unpaired Student's t-test. Representative data for experiments repeated a minimum of three times are shown. For in vivo studies, animal IgG2b concentrations and body weights were evaluated by ANOVA with pairwise comparisons using Dunnett's T-test, Tukey's and Fisher's exact test. Non-parametric analyses of median data were performed using Kruskall-Wallis, and pair-wise comparisons were conducted using the Mann-Whitney test. Significance was set at P ⩽ 0.05. Statistics were performed using Minitab statistical software (Minitab, State College, PA, USA).
RESULTS
Specificity of XRK3F2 for the ZZ domain of p62 p62 is composed of five domains that are critical for proteinprotein interactions required for the formation of signaling complexes that have important roles in BMSC support of MM cell growth and OCL formation ( Figure 1a ). We recently demonstrated that p62-ZZ is required for BMSC enhancement of MMBD. 9 Because BMSC-MM interactions increase TNFα in the MM microenvironment, and NFκB signaling is activated in BMSC as a result of MM cell-BMSC binding, 19 we assessed the relative specificity of XRK3F2 for the p62-ZZ domain of p62 by testing whether XRK3F2 preferentially blocked TNFα rather than IL-1β-induced NFκB signaling, because TNFα utilizes the ZZ domain while IL-1β utilizes the TRAF6 domain of p62 to facilitate NFκB signaling. XRK3F2 inhibits TNFα-induced OCL formation To further assess the relative specificity of XRK3F2 for the ZZ domain, we next tested the effects of XRK3F2 on TNFα and RANKL-induced human OCL formation. We previously found that XRK3F2 inhibited TNFα-induced murine OCL formation by p62 +/ − but not p62 − / − OCL precursors. 8 XRK3F2 dose-dependently inhibited OCL formation by CFU-GM derived from CD11b + cells treated with TNFα at very low concentrations of XRK3F2 (0.1 μM) (Figure 3a ). OCL formation induced by RANKL was only partially inhibited and required higher concentrations of XRK3F2 (1.0-10 μM). This was expected as RANKL signaling utilizes the TRAF6, p38MAPK and ZZ domains of p62 to induce OCL formation. 6, 20 Further, although high-dose XRK3F2 (10μM) blocked OCL formation, it did not trigger caspase activation or other apoptosis-inducing factors in OCL precursors (data not shown). These results suggest that XRK3F2 predominantly inhibits OCL precursor differentiation.
We next assessed the effect of XRK3F2 on TNFα and RANKL-induced expression of OCL differentiation and activation factors in OCL precursors. Consistent with our data in BMSC and primary MM cells, XRK3F2 strongly inhibited TNFα, but only modestly blocked RANKL-induced c-Fos and NFATc1 expression (Figure 3b ). To determine the mechanisms responsible for XRK3F2's inhibition of TNFα-induced OCL formation, we then examined the effects of XRK3F2 on downstream signaling pathways induced by TNFα in OCL precursors. XRK3F2 inhibited Figure 2 . XRK3F2 blocks TNFα-induced signaling processes in MM patient BMSC and MM cells. (a) XRK3F2 blocks TNFα but not IL-1β stimulated NFκB phosphorylation on MM patient BMSC. MM patient BMSC were pre-treated with 10 μg/ml of XRK3F2 or vehicle (0.1% DMSO) for 3 h. Cells were then stimulated with 10 ng/ml of TNFα or IL-1β for the indicated times. Phospho-NFκB (p-NFκB) and NFκB were assayed by western blot using anti-phospho-NFκB and anti-NFκB antibodies. The ratio of p-NFκB to total NFκB at the 5-and 30-min time points for each treatment condition is shown. (b) XRK3F2 inhibited p-IκBα activation by TNFα in MM patient BMSCs. BMSCs were pre-treated with XRK3F2. For assay of degradation of IκBα, cells were stimulated with 10 ng/ml of TNFα for the indicated times and the cell lysates were collected. Total IκBα was assayed by western blot using an IκBα antibody. (c) VCAM-1 expression on representative normal and MM patient BMSCs. VCAM-1 expression was assayed by western blotting. BMSCs were cultured with and without TNFα and XRK3F2 for 48 h. Cell lysates were then collected and VCAM-1 expression measured using an anti-VCAM-1 antibody. (d) IL-6 production by MM patient BMSCs. BMSCs were cultured with and without TNFα and XRK3F2 for 48 h. Cell culture media were collected and IL-6 production measured using an IL-6 ELISA kit. Data are shown as the mean ± s.d. (n = 3). *P o0.01 compared with non-treatment control culture. (e) RANKL production by MM patient BMSCs. BMSCs were cultured with and without TNFα and XRK3F2 for 48 h. Cell culture media were collected and RANKL production measured using a RANKL ELISA kit. Data are shown as the mean ± s.d. (n = 3). *Po0.01 compared with vehicle treatment control culture. (Figure 3c) , which utilizes the p38 domain of p62.
PKCζ and IκBα but not p38 MAPK activation in OCL precursors
XRK3F2 directly inhibits the growth of MM cell lines and primary MM cells but does not affect BMSC viability As we previously reported that XRK3F2 inhibits growth of MM1.S human MM cells, 8 we next evaluated the effects of XRK3F2 on 5TGM1 murine MM cell growth, the MM cell line used in our in vivo model of MMBD, 12 six human MM cell lines and primary MM cells. XRK3F2 significantly inhibited the growth of all six human MM cell lines and primary human MM cells (Figures 4a and b) (patient characteristics are summarized in Table 1 ). The IC 50 of XRK3F2 for 5TGM1 cells was 4.35 μM (Figure 4c) , and 4.6 μM for the human MM1.S cell line. In addition, 5TGM1 cells accumulated XRK3F2, with peak concentrations in the cell pellet of 370 μM after 30 min. Cell concentrations remained above 300 μM for 24 h (Supplementary Figure 2) .
We previously demonstrated that XRK3F2 inhibits murine MM cell growth and human BMSC support of human MM cell growth. 7 Therefore, we evaluated whether XRK3F2 altered the viability and/ or function of primary BMSCs from MM patients and healthy donors and the mechanism of its effects on MM cells. XRK3F2 did not alter BMSC viability (data not shown). XRK3F2 induced apoptosis in MM cells, as demonstrated by cleavage of caspases 9, 7 and 3 after 16 h (Figure 4d ).
XRK3F2 induces new cortical bone formation in MMBD in vivo
Based on these encouraging results, we examined the effects of XRK3F2 in an immunocompetent model of myeloma, as described in the Materials and methods and Supplementary Figure 1 .
The t 1/2 of XRK3F2 in these mice was 10.3 h (data not shown). Consistent with prior studies, 77% of evaluable animals inoculated with 5TGM1 cells (27 of 35) had MM engraftment, as defined by end of study elevation of plasma IgG 2b levels. 12 Body weights and hematocrits did not differ among the treatment and control groups, or in animals receiving high and low XRK3F2 doses (data not shown). Plasma IgG 2b concentrations at the end of dosing were higher in all groups as compared with at stratification, indicating that MM burden increased regardless of if animals received XRK3F2 or vehicle.
μCT and X-ray were used to evaluate bone disease in all animals at the end of the study. Six of seventeen XRK3F2-treated and one vehicle-treated animal demonstrated a marked periosteal reaction on X-ray, suggesting new bone formation along the tibia (Figure 5a) . However, μCT analysis of all animals demonstrated increased cortical bone in all XRK3F2-treated animals, as determined by the ratio of new cortical bone volume to total bone volume (N-BV/T-BV), independent of XRK3F2 dose (Figure 5c ). μCT findings were confirmed by histology ( Figure 6 ). Trabecular bone volumes did not differ between vehicle and XRK3F2-treated animals. Interestingly, no new bone formation was detected in the non-MM-bearing leg of XRK3F2-treated animals, (Figure 5e ), indicating a lack of effect on bone not involved by MM. XRK3F2-treated animals with tumor burdens at the end of study (based on IgG 2b levels) displayed greater cortical bone formation than XRK3F2-treated animals with low tumor burden (Figure 5d ). Further analyses demonstrated no reduction in the volume of the marrow cavity in animals with new cortical bone formation, suggesting that increased endocortical bone formation did not occur within the marrow space (data not shown).
Histologic analysis of tibiae confirmed the presence of new, woven bone (bone that was laid down rapidly, Figure 6f ) in XRK3F2-treated animals but not in vehicle-treated animals ( Figure 6a ). The majority of the periosteal surface of the tibiae of these samples had new bone formation that was localized to one side (Figure 6b + cells were pretreated with XRK3F2 and stimulated with 10 ng/ml of TNFα for the times indicated. Phospho-PKCζ, IκBα and p38 MAPK were assayed using anti-phospho PKCζ, anti-phospho IκBα and anti-phospho p38 MAPK antibodies.
XRK3F2 alters MM cell-BMSC cell interactions by reducing MM cell-derived TNFα in the myeloma microenvironment
To examine the mechanism responsible for the new bone formation observed in vivo, we evaluated whether XRK3F2 alters production of known MM cell-derived OB inhibitors, directly induces OB differentiation or alters MM cell-induced suppression of OB differentiation.
5TGM1 cells were analyzed for their expression of IL-7 and TNFα, known suppressors of OB differentiation that are upregulated in the presence of BMSC (in 5TGM1 cells, DKK1 expression is not upregulated by BMSC, as previously reported 12 ). XRK3F2 did not induce TNFα or IL-7 in 5TGM1 cells cultured with XRK3F2, or induce OB differentiation of primary murine BMSCs or MC4 cells, a mouse calvarial pre-OB cell line, in the absence of MM cells, as assessed by expression of OB differentiation markers Ocn, ALP and Runx2 (data not shown). These results suggest that XRK3F2 affects MM cell-BMSC interactions, rather than either cell type individually.
MM cell-BMSC interactions activate BMSC signaling pathways that inhibit OB differentiation. 6 Therefore, we evaluated whether XRK3F2 alters MM cell-induced inhibition of OB differentiation. Because XRK3F2 blocks TNFα-mediated OCL formation, and TNFα is a major suppressor of OB differentiation that is upregulated in the marrow microenvironment by MM cell-stromal cell interactions, we hypothesized that XRK3F2 reduces OB suppression (allowing differentiation) in the MM bone marrow microenvironment by altering production of TNFα. 5TGM1 cells were cocultured with mBMSC in the presence or absence of XRK3F2. At the end of the culture period, TNFα expression in 5TGM1 cells and mBMSC was evaluated by qPCR. TNFα mRNA expression was significantly upregulated in both 5TGM1 cells and BMSCs following coculture. Interestingly, XRK3F2 prevented coculture-induced upregulation of TNFα mRNA in 5TGM1 cells (Figure 7b ) and in BMSCs. To confirm these findings at the protein level, and to determine whether this reduction in TNFα upregulation was mediated by inhibition of p62 signaling, we repeated the experiment using BMSC from p62KO (p62 .S cells were cultured with 10 μM XRK3F2 for the indicated time and cell lysates were collected. Cleaved and uncleaved caspases 9, 7 and 3 were detected by western blotting using anti-cleaved and uncleaved caspases 9, 7 and 3 specific antibodies. 5 that results in pathologic fractures and severe bone pain. Current treatment strategies focus on OCL inhibition, and to date no bone anabolic agent in MM has been identified that results in significant new bone formation in MM lesions. We recently reported that p62 has a critical role in BMSC support of MM cell growth and OCL formation 9 and identified the p62-ZZ domain, a RIP binding domain involved in atypical PKC and NFkB signaling induced by TNFα, 21 as a potential therapeutic target for MM and MMBD.
In this study we demonstrate that XRK3F2, a novel small molecule antagonist of the p62-ZZ domain, 9 inhibited the growth of primary CD138 + MM cells and human MM cell lines by inducing apoptosis, and did not inhibit BMSC growth or induce BMSC apoptosis in an immunocompetent model of MMBD. Importantly, XRK3F2 induced dramatic, local new bone formation in bones bearing MM in vivo but did not induce new bone formation in bones from the same animals that were not directly inoculated with MM cells. The results demonstrate that XRK3F2 alters the effect of MM on bone.
Possible mechanisms for the bone anabolic effects we observed include direct effects of XRK3F2 on OB or decreased production of OB inhibitory factors by MM cells. Direct effects of XRK3F2 on OB are unlikely, as preliminary studies of XRK3F2 on OB precursors in the absence of MM cells did not change OB differentiation (data ) and XRK3F2, and animals that received IT 5TGM1 injections in the absence of XRK3F2. The tibia shown with 5TGM1 inoculation and XRK3F2 exposure (left) has an aggressive periosteal reaction in the form of delicate rays of periosteal bone that extend away from the bone perpendicularly-creating 'a 'hair on end' appearance (arrow). In addition, a permeative pattern of bone destruction is noted in the fibula (arrowheads). This pattern of bone destruction is associated with rapid growth of the inciting agent, such as in cases of bone metastases and myeloma. In contrast, the center X-ray image (tibia from the contralateral (non-5TGM1 injected) leg of an animal with MM and treated with XRK3F2 has no evidence of a periosteal reaction, though osteopenia is evident. Finally, no periosteal reaction is seen on X-ray of a tibia treated with IT 5TGM1 cells but no XRK3F2. Lytic lesions are visible. (b) μCT images of new bone formation. Fixed tibiae were scanned using a μCT system (vivaCT 40, Scanco Medical). Composite μCT images of the volume of interest for each tibia are shown, and correlate with the bones whose X-ray images are above. New bone formation can clearly be seen along the tibial diaphysis of the tibia that had direct MM cell inoculation and XRK3F2 exposure. No new bone formation is seen in either the contralateral leg of an animal that did have XRK3F2 exposure (center) or the MM-injected control that did not have XRK3F2 exposure. (c) New bone volume is increased in all XRK3F2-treated mice. To compare new bone formation between vehicle and XRK3F2-treated animals, a global threshold was applied to delineate newly formed bone (330) from total bone (180) and from surrounding soft tissue and water. The ratio of new (N) bone volume (BV) as compared with total BV was increased in all XRK3F2 treated mice regardless of IgG 2b level (P = 0.015). *Po0.05 compared with vehicle-treated animals. (d) XRK3F2-treated mice with high tumor burden had more new bone formation. XRK3F2-treated mice with high monoclonal IgG 2b levels (a marker of tumor burden) had significantly more new bone formation than animals with low IgG 2b levels (P = 0.018). *Po0.05 compared with low IgG 2b animals. (e) Effects of XRK3F2 on uninvolved bone. To evaluate whether the effect of XRK3F2 on new bone formation is systemic or occurs only in the presence of tumor, we compared N-BV/T-BV in the non-tumor bearing (left) tibiae of animals treated with vehicle or XRK3F2. New bone volume did not differ significantly between the groups. Data are shown as mean ± s.d. not shown), and XRK3F2 did not have an anabolic effect on bones without tumor. XRK3F2 treatment of MM cells also did not alter production of MM cell-derived OB inhibitory factors, including TNFα and IL-7. Interestingly, however, coculture of 5TGM1 cells with MC4 cells under osteogenic conditions in the presence of low concentrations of XRK3F2 resulted in upregulation rather than suppression of stromal cell Runx2, a critical transcription factor required for OB differentiation that is normally suppressed with MM cell coculture (Figure 7a) . 12, 22 These data suggest that XRK3F2 induces new bone formation by blocking the effects of MM cell-derived inhibitors of OB differentiation in BMSC, such as TNFα, which use signaling complexes formed on the ZZ domain of p62. In support of this hypothesis, we found that XRK3F2 decreased primary MM patient BMSC production of VCAM-1 (Figure 3a) , which mediates adhesive interactions between BMSCs and α 4 β 1 integrin on MM cells 23 and has an important role in BMSC support of tumor growth and MMBD, 1, 6, [24] [25] [26] via its effects on TNFα-induced RANKL and IL-6 (Figures 2d and e) . Our finding that XRK3F2 blocked TNFα induced PKCζ and IκBα phosphorylation in BMSCs when the cells were pretreated with XRK3F2, 8 but only partially blocked IL-6 and RANKL production, suggests that both NFκB and p38MAPK signaling regulate IL-6 and RANKL production by TNFα in BMSCs. Additionally, we previously reported that IL-6 and RANKL production is dependent on both p38MAPK and NFκB signaling in MM patient BMSCs. 6 These results suggest that XRK3F2 may block the TNFα-induced suppression of OB differentiation observed in MM cell-BMSC co-cultures, 27 as XRK3F2 blocks TNFα-mediated signaling in BMSC (Figure 3b) , and upregulation of TNFα in both MM cells and BMSC when they are co-cultured (Figures 7b and c) .
Importantly, OCL were present in the newly formed bone observed in our study. This demonstrates that the new bone had undergone active remodeling that could become normal lamellar bone over time, and that OCL activity in areas of new bone formation is not inhibited. It is likely that the OCL activity seen in the presence of XRK3F2 is induced by RANKL, as RANKL induction of OCL formation is dependent on both TRAF6 (TBS domain of p62) and p38MAPK (p38 domain of p62) signaling. 6, 20 Consistent with this, XRK3F2 only modestly inhibited RANKL-induced OCL formation in vitro (Figure 3a) , though low concentrations of XRK3F2 inhibited TNFα-induced OCL formation. In addition, XRK3F2 blocked OCL precursor differentiation to a lesser extent in the presence of RANKL (Figure 3c ), but did not induce precursor apoptosis (XRK3F2 did not trigger caspase activation or induce apoptosis in OCL precursors, data not shown). This suggests that p62 is critical for normal human OCL precursor differentiation but not survival, and is supported by the finding that p62KO mice have normal basal OCL formation. 28 In our study, new woven bone formation occurred outside the marrow space adjacent to tumor, and was seen only in bones that had been directly inoculated with MM cells. Since OB suppression by MM is a local event, the proximity of new bone to tumor is consistent with the hypothesis that XRK3F2 alters MM suppression of OB, suggesting that XRK3F2 allowed MM-exposed OB to respond to anabolic stimuli released or expressed by OCL during bone remodeling, and that OCL activity may be required for the anabolic effects of XRK3F2. The results of XRK3F2 on MM cells in vitro also likely reflect a decrease in NFκB signaling. XRK3F2 directly activated caspases 3, 7 and 9 in MM cells (Figure 4d ) and decreased NFκB signaling in MM results in the aggregation of caspase 8 and its downstream effector caspases. 29 Thus, high concentrations of XRK3F2 induced apoptosis in MM cells. The immunocompetent MMBD model used to evaluate the efficacy of XRK3F2 in this study used animals with well-established disease (animals were implanted with MM cells 14 days before treatment initiation), and at end of treatment serum IgG2b levels were significantly higher than levels at stratification, demonstrating continued tumor growth. This was expected, as plasma concentrations of XRK3F2 were not maintained above the IC 50 for murine MM cells (4.35 μM) for more than 30 min following the 40 mg/kg dose. The continued tumor growth resulted in extensive bone destruction and osteolysis throughout the marrow space in both vehicle-treated and XRK3F2-treated animals.
To our knowledge, p62 has not been previously targeted in BMSCs or myeloma cells to prevent tumor progression and bone destruction. We suggest that targeting p62 in MM may be an attractive therapeutic strategy with little or no obvious nonspecific toxicity, as our preliminary data suggest that targeting p62
should not block normal hematopoiesis, 9 and p62 − / − mice have no phenotype aside from adult onset diabetes. 30 We anticipate that XRK3F2 or its derivatives, in combination with more potent anti-myeloma agents such as bortezomib, 31, 32 should have a profound therapeutic effect on MMBD.
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